Sanofi SA (NYSE:SNY) – Stock analysts at Svb Leerink issued their Q1 2020 EPS estimates for Sanofi in a report released on Tuesday, February 11th. Svb Leerink analyst G. Porges forecasts that the company will post earnings per share of $0.81 for the quarter. Svb Leerink has a “Market Perform” rating on the stock. Svb Leerink also issued estimates for Sanofi’s Q2 2020 earnings at $0.78 EPS, Q3 2020 earnings at $1.03 EPS, Q4 2020 earnings at $0.82 EPS, FY2023 earnings at $4.31 EPS and FY2024 earnings at $4.61 EPS.
Several other analysts have also recently commented on the company. Leerink Swann started coverage on Sanofi in a report on Tuesday. They issued a “market perform” rating and a $58.00 price target for the company. DZ Bank restated a “neutral” rating on shares of Sanofi in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Sunday, January 5th. They noted that the move was a valuation call. Barclays cut Sanofi from an “equal weight” rating to an “underweight” rating in a report on Friday, December 6th. Finally, Liberum Capital cut Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $52.25.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Atria Investments LLC bought a new stake in shares of Sanofi in the 2nd quarter worth about $225,000. Reilly Financial Advisors LLC lifted its holdings in shares of Sanofi by 8,332.8% in the 3rd quarter. Reilly Financial Advisors LLC now owns 26,985 shares of the company’s stock worth $1,250,000 after acquiring an additional 26,665 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Sanofi by 21.8% in the 3rd quarter. Signaturefd LLC now owns 14,001 shares of the company’s stock worth $649,000 after acquiring an additional 2,507 shares during the last quarter. Advisor Partners LLC lifted its holdings in shares of Sanofi by 17.5% in the 3rd quarter. Advisor Partners LLC now owns 9,332 shares of the company’s stock worth $432,000 after acquiring an additional 1,392 shares during the last quarter. Finally, Vista Private Wealth Partners. LLC bought a new stake in shares of Sanofi in the 3rd quarter worth about $96,000. Institutional investors own 7.04% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: Hedge Funds Explained
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.